Verax Research IPO

Verax Research Services, Inc., a Delaware C-Corporation founded in July 2017 (URL: www.veraxresearch.com) has submitted a Tier 2 Regulation A Filing (the “IPO Offering”) to the SEC and anticipates a near-term effective date at a $6.25 per share price and a valuation of $406MM.

OUR SERVICESHemp products
– from start to finished.

High quality Hemp starts, tested by Verax Research
https://veraxresearch-ipo.com/wp/wp-content/uploads/2019/08/Picture1.jpg
CBD, THC, Terpenes, Heavy Metals, Pesticide Residues, and more…
https://veraxresearch-ipo.com/wp/wp-content/uploads/2019/08/tetramethyluronium-835793_1920-1-e1565312238680.png
Down to the smallest detail
https://veraxresearch-ipo.com/wp/wp-content/uploads/2019/08/survey-1594962_1920.jpg
Clinical trials
Processing and Extraction
https://veraxresearch-ipo.com/wp/wp-content/uploads/2019/08/buy-3692440_1920.jpg
Secure Hemp Constituent Transactions

The Verax Research DifferenceOur Team

Founded by proven and trusted Pharmaceutical and Medical Device executives with over 120 years of Pharmaceutical and Medical Device product testing, design and development with a singular objective: “Ensure hemp research and product development lead to safe and effective healthcare commercial products.”

Initial Public OfferingThe Opportunity

The Offering

8,000,000 shares of common stock (the “shares”) are being offered by Verax Research Services, Inc., a development stage Delaware corporation on a best-efforts basis.

Company is offering up to a maximum of $50,000,000 of such Shares.